• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

Validation Data Gallery

  • 1X10^6 HEK CTLA4 transient transfected cells (red) and HEK parental cells were surface stained with 0.5 µg CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl). Cells were not fixed.

    1X10^6 HEK CTLA4 transient transfected cells (red) and HEK parental cells were surface stained with 0.5 µg CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl). Cells were not fixed.

  • Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.25ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) and CL488 CD3 (CL488-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.25ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.25ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

    Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.25ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) and CL488 CD3 (CL488-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.25ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.25ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

  • Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transcription Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.

    Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transcription Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.

  • 1x10^6 PHA-treated (3d) human PBMCs were surface stained with CL405 CD3 (CL405-65151) then fixed and permeabilized and stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl). Right: 1x10^6 PHA-treated (3d) human PBMCs were fixed and permeabilized then stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were fixed and permeabilized then stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transfripction Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.

    1x10^6 PHA-treated (3d) human PBMCs were surface stained with CL405 CD3 (CL405-65151) then fixed and permeabilized and stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl). Right: 1x10^6 PHA-treated (3d) human PBMCs were fixed and permeabilized then stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were fixed and permeabilized then stained with 0.5ug CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transfripction Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.

  • HeLa cells transfected with human CTLA-4 were immunostained with CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (1:500, magenta). Nuclei were stained with DAPI (cyan). Epifluorescence images were acquired with a 40x objective and post-processed. Comment: Immunostaining with CL647-ctl can be performed live or after formaldehyde fixation.

    HeLa cells transfected with human CTLA-4 were immunostained with CoraLite® Plus 647 conjugated CTLA-4 VHH (CL647-ctl) (1:500, magenta). Nuclei were stained with DAPI (cyan). Epifluorescence images were acquired with a 40x objective and post-processed. Comment: Immunostaining with CL647-ctl can be performed live or after formaldehyde fixation.

ChromoTek CoraLite® Plus 647-conjugated CTLA4 VHH

CL647-ctla targets CTLA4 in FC and IF applications and shows reactivity with Human samples.
Cat No. CL647-ctl

Host/Type

Alpaca VHH

Reactivity

Human

Applications

FC, IF

Conjugate

CoraLite® Plus 647

Synonyms

CTLA4-Nanobody, CTLA4-Single domain antibody (sdAb), CD152, Cytotoxic T-Lymphocyte-associated antigen 4, CTLA4, CTLA-4

Formats:  CoraLite ® Plus 647
Size/Concentration: 

-/ -

ご購入について

国内販売は「コスモ・バイオ株式会社」を通じて行っております。お見積り・ご注文はお近くの販売代理店へご連絡ください。

国内在庫・納期について

約2万点のプロテインテック製品をコスモバイオ社物流センター（国内）に在庫しています。国内在庫の有無はコスモバイオ社ホームページの「品番検索」でカタログ番号を検索して確認できます。

保証・サポートについて

テクニカルサポートまたはご購入後1年間の交換／補填対応を承ります。詳細はこちらをご覧ください。

Product Information

CL647-ctla targets CTLA4 in FC and IF applications and shows reactivity with Human samples.

ApplicationsFC, IF
ReactivityHuman
ConjugateCoraLite® Plus 647
TypeNanobody
ClassRecombinant
HostAlpaca
Affinity22 nM
Molecular Weight14.005 kDa
FormLiquid
Excitation/Emission Maxima Wavelengths654 nm / 674 nm
RRIDAB_3101939
Storage Buffer500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide
Storage ConditionStore at -20°C
BackgroundCTLA-4, also known as CD152, belonging to the immunoglobulin superfamily, is primarily found on activated T cells and regulatory T cells (Tregs). CTLA-4 is closely related to the T-cell costimulatory CD28, and both molecules bind to B7-1 and B7-2 on antigen-presenting cells. CTLA-4 acts as a negative regulatory molecule of T-cell responses. Besides the full-length transmembrane form, CTLA-4 also exists in a truncated soluble form (sCTLA-4).